华法林抗凝治疗慢性重度心力衰竭合并持续性心房颤动的临床疗效

Clinical Effect of Warfarin Anticoagulant Therapy for Treatment of Chronic Severe Heart Failure with Persistent Atrial Fibrillation

目的探讨华法林抗凝治疗慢性重度心力衰竭合并持续性心房颤动的临床疗效。方法收集2012年1月至2014年7月于我院治疗慢性重度心力衰竭合并持续性心房颤动的109例患者为研究对象,将其随机分为实验组和对照组,对照组使用阿司匹林口服治疗,实验组使用华法林口服治疗,对两组患者临床疗效及并发症的发生率进行对比分析。结果实验组:治疗前左室射血分数(left ventricular ejection fractions,LVEF)(mm)25.9±9.7,治疗后LVEF(mm)30.6±10.3;心房颤动转复率42例(76.36%);并发症:栓塞事件2例,出血6例,发生率14.55%。对照组:治疗前LVEF(mm)25.2±10.4,治疗后LVEF(mm)26.5±10.7;心房颤动转复率29例(53.70%);并发症:栓塞事件9例,出血6例,发生率27.78%。两组对比均P<0.05,存在统计学差异。结论华法林抗凝治疗慢性重度心力衰竭合并持续性心房颤动具有较好的临床疗效,推荐内科医师应用。

Objective To investigate the clinical efficacy of warfarin anticoagulation for treatment of severe chronic heart failure with persistent atrial fibrillation. Methods From January 2012 to July 2014, 109 cases with severe chronic heart failure with persistent atrial fibrillation in the second people＇s hospital of Yuhong District were selected as the research object, they were randomly divided into experimental group and control group; the control group received aspirin therapy, and the experimental group used oral warfarin therapy; the clinical efficacy and incidence rate of complications were compared between two groups. Results In the experimental group, the left ventricular ejection fraction（left ventricular ejection fractions, LVBF）is respectively （25.9 ~9.7）ram and （30.6~10.3）mm before and after treatment; atrial fibrillation cardioversion rate was 76.36% （42 cases）; the occurrence rate of complications was 14.55%, including 2 cases of thromboembolism, bleeding in 6 cases. In the control group, LVEF is respectively （25.2±10.4）mm and （26.5±10.7）mm before and after treatment; atrial fibrillation cardioversion rate was 53.70%（29 cases）; the occurrence rate of complications was 27.78%, including 9 cases of thromboembolism and hemorrhage in 6 cases. The comparison between two groups, P〈0.05, there was statistical difference. Conclusion Clinical efficacy of warfarin for treatment of chronic severe heart failure with persistent atrial fibrillation is remarkable. It is recommended that internal physicians using the therapeutic regimen.